Richard M. Ransohoff, MD is VP, Neuroimmunology and Acute Neurology (from October, 2014) at Biogen and Adjunct Professor of Pathology, Case Western Reserve University (CWRU). He directs a team of >40 researchers and clinicians, responsible for developing drug for acute and chronic neurodegenerative disease, from target identification through phase II proof of concept.
After AB (Literature) from Bard College and MD from CWRU School of Medicine, residencies in Internal Medicine at Mt. Sinai Medical Center (Cleveland) and Neurology (Cleveland Clinic [CCF]), he performed post-doctoral research work (Dept Molecular Biology and Microbiology, CWRU). From 1984-2014 he was Staff Member at CCF where he founded and directed the Neuroinflammation Research Center (2005-2014) and served (1984-2014) as Staff Neurologist, CCF Mellen Center for MS Treatment and Research. He lists more than 400 scientific articles and reviews in PubMed (Google Scholars h-index 106 in January 2017), and has trained >70 students and post-docs who now hold positions in academics and industry. He’s served as regular member of NIH Study Sections and Chaired Scientific Review Panel B, National Multiple Sclerosis Society; Section Editor, J Immunology; Advisory Editorial Board, Trends Immunol (2003-present); Highlights Advisory Board, Nature Rev Immunol, Associate Editor of Neurology® and founding Editor of Neurology®: Neuroimmunology and Neuroinflammation. He received the John J. Dystel Award for MS Research from the National MS Society and American Academy of Neurology (2012) and was named in the “Best Doctors” compendium from 1996-2014 for his expertise in patient care of individuals with MS and related conditions.
« Go Back